塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者有效率及肿瘤标志物的影响效果研究  

Study on the Effect of Celecoxib combined with IMRT on the Effective Rate and Tumor Markers in Elderly Patients with Advanced Non-small Cell Lung Cancer

作　　者：王淑世 任兴帅 贺珊珊 尚晓璐 WANG Shushi;REN Xingshuai;HE Shanshan;SHANG Xiaolu(Zouping People's Hospital,Binzhou 256200,China)

机构地区：[1]邹平市人民医院,山东滨州256200

出　　处：《中国医药指南》2021年第31期4-6,共3页Guide of China Medicine

摘　　要：目的探讨塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者有效率及肿瘤标志物的影响效果。方法选取来院治疗的非小细胞肺癌患者80例,并将患者随机划分成对照组和观察组,对对照组老年中晚期非小细胞肺癌患者施加单纯IMRT放疗,对观察组患者实施塞来昔布联合IMRT的治疗。观察两组患者的有效率,分为CR、PR、SD、PD,计算ORR的数据。另外观察两组患者治疗前后的CA125、CEA、SCCA的标志物水平。结果对比分析对照组和观察组老年中晚期非小细胞肺癌患者,明确观察组患者近期治疗有效率为28例(70.00%),明显高于对照组患者15例(37.50%),有统计学差异(χ^(2)=8.498,P=0.004)。尽管对照组老年中晚期非小细胞肺癌患者在接受常规临床治疗之后,患者血清肿瘤标志物水平会下降,但是相应指标变化的明显程度与观察组患者相比还存在一定差距。也就是说,通过塞来昔布联合IMRT对老年中晚期非小细胞肺癌患者进行综合治疗后,患者血清肿瘤标志物水平的降低幅度明显高于同期对照组患者(P<0.05)。结论了解到对老年中晚期非小细胞肺癌患者进行临床治疗时,需要结合患者身体状况和疾病表现强化塞来昔布联合IMRT疗法的现实作用,并利用标准精细的放射线治疗设备对患者进行有效治疗,借此调节老年中晚期非小细胞肺癌患者血清肿瘤标志物水平,防止老年中晚期非小细胞肺癌患者体内癌变器官越来越严重,使得老年中晚期非小细胞肺癌患者近期疗效和远期生存率上升到一定高度。Objective To investigate the effect of celecoxib combined with IMRT on the effective rate and tumor markers in elderly patients with advanced non-small cell lung cancer.Methods A total of 80 patients with non-small cell lung cancer who came to the hospital for treatment were selected,and the patients were randomly divided into a control group and an observation group.The control group was given IMRT radiotherapy for the elderly patients with advanced non-small cell lung cancer,and the observation group was given celecoxib The treatment of cloth combined with IMRT.Observe the effective rate of the two groups of patients,divided into CR,PR,SD,PD,and calculate the ORR data.In addition,the levels of CA125,CEA and SCCA markers before and after treatment were observed in the two groups.Results A comparative analysis of the control group and the observation group of elderly patients with advanced non-small cell lung cancer showed that the effective rate of the observation group was 28 cases(70.00%),which was significantly higher than that of the control group,15 cases(37.50%).There was a statistical difference(χ^(2)=8.498,P=0.004).Although the level of serum tumor markers in the control group of elderly patients with advanced non-small cell lung cancer after receiving routine clinical treatment will decrease,there is still a certain gap in the degree of change in the corresponding index compared with the observation group.In other words,before and after comprehensive treatment of elderly patients with advanced non-small cell lung cancer through celecoxib combined with IMRT,the reduction in serum tumor marker levels was significantly higher than that of patients in the control group during the same period(P<0.05).Conclusion It is understood that in the clinical treatment of elderly patients with advanced non-small cell lung cancer,it is necessary to strengthen the practical effect of celecoxib combined with IMRT based on the patient's physical condition and disease performance,and use standard and sophisticated radiothe

关 键 词：非小细胞肺癌 塞来昔布 IMRT 老年 中晚期 有效率 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]